Kamada (NASDAQ:KMDA) is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.
Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S. Food and Drug Administration for patients with alpha‐1 antitrypsin deficiency who have emphysema. In addition, Kamada holds commercial rights to KEDRAB®, a rabies immune globulin product used for post‐exposure prophylaxis, and has distributed plasma‐derived factor IX concentrate (marketed under various brands) for patients with hemophilia B. These products are manufactured at Kamada’s vertically integrated facilities in Israel, and are sold through its U.S. subsidiary and distributors across North America, Europe and other international markets.
Building on its established product base, Kamada maintains a development pipeline that includes hyperimmune therapies and monoclonal antibody candidates, such as investigational treatments for COVID‐19. The company has collaborated with academic and industry partners to advance preclinical and clinical studies of novel plasma‐derived and recombinant proteins, aiming to expand its reach into additional rare disease indications and emerging infectious diseases.
Founded in 1990, Kamada has grown into a global specialty biopharma organization while retaining a strong connection to its Israeli roots. Ronen Zohar, who has served as Chief Executive Officer since 2011, leads a management team experienced in regulatory affairs, manufacturing scale-up and strategic partnerships. Through ongoing investments in research, production capacity and international marketing, Kamada seeks to enhance patient access to its therapies and pursue new opportunities in the plasma‐derived protein market.
